251 related articles for article (PubMed ID: 30069765)
21. Tropomyosin Receptor Kinase Inhibitors for the Treatment of TRK Fusion Cancer.
Laetsch TW; Hong DS
Clin Cancer Res; 2021 Sep; 27(18):4974-4982. PubMed ID: 33893159
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.
Drilon A; Laetsch TW; Kummar S; DuBois SG; Lassen UN; Demetri GD; Nathenson M; Doebele RC; Farago AF; Pappo AS; Turpin B; Dowlati A; Brose MS; Mascarenhas L; Federman N; Berlin J; El-Deiry WS; Baik C; Deeken J; Boni V; Nagasubramanian R; Taylor M; Rudzinski ER; Meric-Bernstam F; Sohal DPS; Ma PC; Raez LE; Hechtman JF; Benayed R; Ladanyi M; Tuch BB; Ebata K; Cruickshank S; Ku NC; Cox MC; Hawkins DS; Hong DS; Hyman DM
N Engl J Med; 2018 Feb; 378(8):731-739. PubMed ID: 29466156
[TBL] [Abstract][Full Text] [Related]
23. Targeting TRK: A fast-tracked application of precision oncology and future directions.
Kojadinovic A; Laderian B; Mundi PS
Crit Rev Oncol Hematol; 2021 Sep; 165():103451. PubMed ID: 34389458
[TBL] [Abstract][Full Text] [Related]
24. Belgian expert consensus for tumor-agnostic treatment of NTRK gene fusion-driven solid tumors with larotrectinib.
Awada A; Berghmans T; Clement PM; Cuppens K; De Wilde B; Machiels JP; Pauwels P; Peeters M; Rottey S; Van Cutsem E
Crit Rev Oncol Hematol; 2022 Jan; 169():103564. PubMed ID: 34861380
[TBL] [Abstract][Full Text] [Related]
25. Oncogenic TRK fusions are amenable to inhibition in hematologic malignancies.
Taylor J; Pavlick D; Yoshimi A; Marcelus C; Chung SS; Hechtman JF; Benayed R; Cocco E; Durham BH; Bitner L; Inoue D; Chung YR; Mullaney K; Watts JM; Diamond EL; Albacker LA; Mughal TI; Ebata K; Tuch BB; Ku N; Scaltriti M; Roshal M; Arcila M; Ali S; Hyman DM; Park JH; Abdel-Wahab O
J Clin Invest; 2018 Aug; 128(9):3819-3825. PubMed ID: 29920189
[TBL] [Abstract][Full Text] [Related]
26. Detection of Tumor NTRK Gene Fusions to Identify Patients Who May Benefit from Tyrosine Kinase (TRK) Inhibitor Therapy.
Hsiao SJ; Zehir A; Sireci AN; Aisner DL
J Mol Diagn; 2019 Jul; 21(4):553-571. PubMed ID: 31075511
[TBL] [Abstract][Full Text] [Related]
27. Discovery of the Next-Generation Pan-TRK Kinase Inhibitors for the Treatment of Cancer.
Liu Z; Yu P; Dong L; Wang W; Duan S; Wang B; Gong X; Ye L; Wang H; Tian J
J Med Chem; 2021 Jul; 64(14):10286-10296. PubMed ID: 34253025
[TBL] [Abstract][Full Text] [Related]
28. The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomas.
DuBois SG; Laetsch TW; Federman N; Turpin BK; Albert CM; Nagasubramanian R; Anderson ME; Davis JL; Qamoos HE; Reynolds ME; Cruickshank S; Cox MC; Hawkins DS; Mascarenhas L; Pappo AS
Cancer; 2018 Nov; 124(21):4241-4247. PubMed ID: 30204247
[TBL] [Abstract][Full Text] [Related]
29. Emerging Targeted Therapy for Tumors with
Kheder ES; Hong DS
Clin Cancer Res; 2018 Dec; 24(23):5807-5814. PubMed ID: 29986850
[TBL] [Abstract][Full Text] [Related]
30. A Tumor-Agnostic NTRK (TRK) Inhibitor.
Huang FW; Feng FY
Cell; 2019 Mar; 177(1):8. PubMed ID: 30901551
[TBL] [Abstract][Full Text] [Related]
31. Targeting NTRK fusion in non-small cell lung cancer: rationale and clinical evidence.
Ricciuti B; Brambilla M; Metro G; Baglivo S; Matocci R; Pirro M; Chiari R
Med Oncol; 2017 Jun; 34(6):105. PubMed ID: 28444624
[TBL] [Abstract][Full Text] [Related]
32. [A Case of Pediatric Soft Tissue Sarcoma with LMNA-NTRK1 Gene Fusion Treated with Larotrectinib under Single Patient Expanded Access System].
Kato S; Fujimura J; Nozaki Y; Yamaguchi S; Takagi T; Hayashi T; Saito T; Henry D; Ku N; Suehara Y
Gan To Kagaku Ryoho; 2019 Oct; 46(10):1595-1597. PubMed ID: 31631147
[TBL] [Abstract][Full Text] [Related]
33. [NTRK Fusions: A new way of treatment for gastro-intestinal tumor?].
Ouali K; Pellat A; Cohen R; Svrcek M; Penault-Llorca F; André T
Bull Cancer; 2020 Apr; 107(4):447-457. PubMed ID: 32067719
[TBL] [Abstract][Full Text] [Related]
34. Larotrectinib followed by selitrectinib in a novel
Goh XN; Seng MS; Loh AHP; Gupta A; Chang KTE; Iyer P
J Oncol Pharm Pract; 2021 Mar; 27(2):485-489. PubMed ID: 32693686
[TBL] [Abstract][Full Text] [Related]
35. TRK Inhibition: A New Tumor-Agnostic Treatment Strategy.
Kummar S; Lassen UN
Target Oncol; 2018 Oct; 13(5):545-556. PubMed ID: 30276762
[TBL] [Abstract][Full Text] [Related]
36. A novel NCOR2-NTRK1 fusion detected in a patient of lung adenocarcinoma and response to larotrectinib: a case report.
Zhang L; Liu H; Tian Y; Wang H; Yang X
BMC Pulm Med; 2021 Apr; 21(1):125. PubMed ID: 33865348
[TBL] [Abstract][Full Text] [Related]
37. Design, synthesis, and Structure-Activity Relationships (SAR) of 3-vinylindazole derivatives as new selective tropomyosin receptor kinases (Trk) inhibitors.
Duan Y; Wang J; Zhu S; Tu ZC; Zhang Z; Chan S; Ding K
Eur J Med Chem; 2020 Oct; 203():112552. PubMed ID: 32702585
[TBL] [Abstract][Full Text] [Related]
38. The potential of neurotrophic tyrosine kinase (NTRK) inhibitors for treating lung cancer.
Passiglia F; Caparica R; Giovannetti E; Giallombardo M; Listi A; Diana P; Cirrincione G; Caglevic C; Raez LE; Russo A; Rolfo C
Expert Opin Investig Drugs; 2016; 25(4):385-92. PubMed ID: 26881293
[TBL] [Abstract][Full Text] [Related]
39. TRK Inhibitor Shows Early Promise.
Cancer Discov; 2016 Jan; 6(1):OF4. PubMed ID: 26603524
[TBL] [Abstract][Full Text] [Related]
40. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials.
Hong DS; DuBois SG; Kummar S; Farago AF; Albert CM; Rohrberg KS; van Tilburg CM; Nagasubramanian R; Berlin JD; Federman N; Mascarenhas L; Geoerger B; Dowlati A; Pappo AS; Bielack S; Doz F; McDermott R; Patel JD; Schilder RJ; Tahara M; Pfister SM; Witt O; Ladanyi M; Rudzinski ER; Nanda S; Childs BH; Laetsch TW; Hyman DM; Drilon A
Lancet Oncol; 2020 Apr; 21(4):531-540. PubMed ID: 32105622
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]